DPP4 and type 2 diabetes mellitus: A total of 1 161 254 adults with type 2 diabetes mellitus initiating therapy with low‐affinity cardiac mitoKATP channel sulfonylureas, high‐affinity sulfonylureas, and DPP‐4 inhibitors were identified.